PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media31220210.18565/pharmateca.2019.7.00-00ArticlesСтатьиReview ArticlePrognostic markers for testicular germ cell tumors. Research perspectivesПрогностические маркеры при герминогенных опухолях яичка. Перспективы исследованийZhukovaAnna E.ЖуковаА. Еa.galatonova@yandex.ruProtsenkoS. AПроценкоС. АNovikA. VНовикА. ВYurlovD. OЮрловД. ОN.N. Petrov National Medical Research Center of OncologyНациональный медицинский исследовательский центр онкологии им. Н.Н. Петрова15072019267VOL 26, NO7 (2019)ТОМ 26, №7 (2019)212603032023Copyright ©; 2019, Bionika MediaCopyright ©; 2019, ООО «Бионика Медиа»2019Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/312202

In recent years, there has been significant progress in the treatment of disseminated testicular germ cell tumors (GCTs). More recently, patients with this diagnosis were considered doomed. Now we are talking about the potential cure for each patient, regardless of the dissemination process. These achievements are atributable not only to the development of chemotherapy and more intensive surgery, but also to increased diagnostic capabilities, a rational tactic of treating patients depending on prognostic factors. As a result of the study of the profiles of gene expression and the spectrum of molecular damage, genes determining the susceptibility to sporadic, hereditary forms of GCTs were identified. The article presents the modern molecular genetic characteristics of GCTs, as well as the analysis of inherited factors that predispose to the development of GCTs and signaling cascades involved in oncogenesis.

В последние годы наблюдается значительный прогресс в лечении диссеминированных герминогенных опухолей (ГО) яичка. Еще недавно больные с этим диагнозом считались обреченными. Сейчас мы говорим о потенциальной возможности излечения каждого больного независимо от диссеминации процесса. Эти достижения обусловлены не только развитием химиотерапии и более интенсивной хирургией, но и возросшими диагностическими возможностями, рациональной тактикой лечения больных в зависимости от прогностических факторов. В результате исследования профилей генной экспрессии и спектра молекулярных повреждений выявлены гены, определяющие предрасположенность к спорадическим, наследственным формам ГО. В статье представлены современные молекулярно-генетические характеристики ГО, а также анализ наследуемых факторов, которые предрасполагают к развитию ГО и сигнальных каскадов, вовлеченных в онкогенез.

germ cell tumorsprognostic factorsbiomarkersdiagnosticsmutationsгерминогенные опухолифакторы прогнозабиомаркерыдиагностикамутацииSilverberg E. Statistical and epidemiological data on urological cancer Cancer 2017;60:692-717.Albers P., Albrecht W., Algaba F., et al. Guidelines on Testicular Cancer. Eur Urol. 2016;48:885-94.Матвеев В.Б, Волкова М.И. Опухоли яичка и паратестикулярных тканей. Клиническая онкоурология. Под ред. Б.П. Матвеева. М., 2018. C. 617-84.Lange P.H., Millan J.L., Stigbrand T., et al. Placental alkaline phosphatase as a tumor marker for seminoma. Cancer Res. 2013;42:3244-47.Kawai K., Kojima T., Miyanaga N., et al. Lectin-reactive alphafetoprotein as a marker for testicular tumor activity. int J Urol. 2005;12(3):284-89.Ellinger J., Muller S.C., Stadler T.C., et al. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol. 2017;29(2):124-29. Doi: 10.1016/j.urolonc.2009.05.010.Ellinger J., Bastian P.J., Ellinger N., et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett. 2018;264(2):274-80. Doi: 10.1016/j.canlet.2008.01.038.Sozzi G., Conte D., Mariani L., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2018;61:4675-78.Lu M., Zhang Q., Deng M., et al. An analysis of human microRNA and disease associations. PLoS ONE. 2018;3:3420. Doi: 10.1371/journal. pone.0003420.Iorio M.V., Croce C.M. MicroRNAs in Cancer: Small Molecules With a Huge impact. Am Soc Clin Oncol. 2018;27:5848-56. Doi: 10.1200/ JC0.2009.24.0317.Rigoutsos i., Huynh T, Miranda K., et al. Short blocks from the noncoding parts of the human genome have instances within nearly all known genes and relate to biological processes. Proc Natl Acad Sci. USA. 2016;103:6605-10.Murray M.J., Coleman N. Testicular cancer: a new generation of biomarkers for malignant germ cell tumours. Nat Rev Urol. 2018;9:298-300. Doi: 10.1038/nrurol.2012.86.Belge G., Dieckmann K.-P, Spiekermann M., et al. Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors? Eur Urol. 2012;61:1068-69. Doi: 10.1016/j.eururo.2012.02.037.Murray M.J., Halsall D.J., Hook C.E., et al. identification of microRNAs From the miR-371 373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am J Clin Pathol. 2017;135:119-25. Doi: 10.1309/AJCPOE11KEYZCJHT.GillisA.J.M., Rijlaarsdam M.A., Eini R., et al. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germcell cancer patients:aproof of principle. Mol Oncol. 2018;7:1083-92. Doi: 10.1016/j.molonc.2013.08.002.Dieckmann K.-P., Spiekermann M., Balks T., et al. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer. 2017;107:1754-60. Doi: 10.1038/bjc.2012.469.Syring I., Bartels J., Holdenrieder S., et al. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J Urol. 2015;193:331-37. Doi: 10.1016/j.juro.2014.07.010.Horwich A, Shipley J., Huddart R. Testicular germcell cancer. Lancet. 2016;367;754-65.Rodriguez S., Jafer O., Goker H., et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i (12p) and amplification at 12p11.2-p12.1. Oncogene. 2019;22;1880-91.ClarkA.T, Rodriguez R.T., Bodnar M.S., et al. Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. Stem Cells. 2017;22:169-79.Oosterhuis J.W., Looijenga L.H. Testicular germ-cell tumours in a broader perspective. Nat Rev Canc. 2015;5:210-22.Skakkebaek N.E., Rajpert-De Meyts E., Main K.M. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod. 2017;16:972-78.Shen H., Shih J., Hollern D.P., et al. Integrated molecular characterization of testicular germ cell tumors. Cell Rep. 2018;23(11):3392-406. Doi: 10.1016/j.celrep.2018.05.039.Boublikova L., Buchler T., Stary J., et al. Molecular biology of testicular germ cell tumors: unique features awaiting clinical application. Crit Rev Oncol Hematol. 2014;89(3):366-85. Doi: 10.1016/j.critrevonc.2013.10.001.Jamieson E.R., Lippard S J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 2017;99:2467-98.Heidenreich A., Schenkman N.S., Sesterhenn I.A., et al. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours. Apmis. 1998;106:90-9.Bagrodia A., Lee B.H., Lee W., et al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol. 2016;34(33):4000-7. Doi: 10.1200/JCO.2016.68.7798.Lafin J.T., Bagrodia A., Woldu S., et al. New insights into germ cell tumor genomics. ANDROLOGYISSN. 2019;2047-919. Doi: 10.1111/andr.12616.Chee J.L., Saidin S., Lane D.P., et al. Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle. 2018;12:278-88. Doi: 10.4161/cc.23054.Vassilev L.T., Vu B.T., Graves B., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303:844-48.Kersemaekers A.M., Mayer F., Molier M., et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol. 2002;20: 1551-61.Koster R., Timmer-Bosscha H., Bischoff R., et al. Disruption of the MDM2-p53 interaction strongly potentiates p53- dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis. 2011;2:e148. Doi: 10.1038/cddis.2011.33.Voon Y.L., Ahmad M., Wong PF., et al. Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity. Oncol Rep. 2015;34:1692-700. Doi: 10.3892/or.2015.4177.Zanjirband M., Edmondson R.J., Lunec J. Preclinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget. 2016;7:40115-34. Doi: 10.18632/oncotarget.9499.Deben C., Wouters A., Op de Beeck K., et al. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Oncotarget. 2015;6:22666-79.Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer. 2013;49(6):1374-403. Doi: 10.1016/j.ejca.2012.12.027.Fossa S.D., Klepp O., Paus E. Neuron specific enolase: a serum tumor marker in seminoma. Br J Cancer. 1992;65(2):297-99.Ferraro S., Trevisiol C., Gion M., Panteghini M. Human chorionic gonadotropin assays for testicular tumors: closing the gap between clinical and laboratory practice. Clin Chem. 2018;64: 270-78. Doi: 10.1373/clinchem.2017.275263.Давыдов М.И., Ганцев Ш.Х., Онкология: учебник. 2019. C. 801-920.